B
Bayard L. Powell
Researcher at Wake Forest Baptist Medical Center
Publications - 334
Citations - 25265
Bayard L. Powell is an academic researcher from Wake Forest Baptist Medical Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 67, co-authored 319 publications receiving 23225 citations. Previous affiliations of Bayard L. Powell include University of Rochester & Wayne State University.
Papers
More filters
Journal ArticleDOI
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Journal ArticleDOI
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman,Erin P. Demakos,Bercedis L. Peterson,Alice B. Kornblith,Jimmie C. Holland,Rosalie Odchimar-Reissig,Richard Stone,Douglas A. Nelson,Bayard L. Powell,Carlos M. DeCastro,John Ellerton,Richard A. Larson,Charles A. Schiffer,James F. Holland +13 more
TL;DR: Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care.
Journal ArticleDOI
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B
Robert J. Mayer,Roger B. Davis,Celia A. Schiffer,Deborah T. Berg,Bayard L. Powell,Philip Schulman,George A. Omura,Joseph O. Moore,O R McIntyre,Frei E rd +9 more
TL;DR: The concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger is supported and the results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.
Journal ArticleDOI
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F. List,Gordon W. Dewald,John M. Bennett,A. Giagounidis,Azra Raza,Eric J. Feldman,Bayard L. Powell,Peter L. Greenberg,Deborah A. Thomas,Richard Stone,Craig B. Reeder,Kenton Wride,John Patin,Michele Schmidt,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion.
Journal ArticleDOI
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci,Kati Maharry,Yue-Zhong Wu,Michael D. Radmacher,Krzysztof Mrózek,Dean Margeson,Kelsi B. Holland,Susan P. Whitman,Heiko Becker,Sebastian Schwind,Klaus H. Metzeler,Bayard L. Powell,Thomas H. Carter,Jonathan E. Kolitz,Meir Wetzler,Andrew J. Carroll,Maria R. Baer,Michael A. Caligiuri,Richard A. Larson,Clara D. Bloomfield +19 more
TL;DR: The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms.